Center forBioethics and Department of History andSociology of Science, University ofPennsylvania, Philadelphia, PA 19104, USA.
Am J Public Health. 2010 Oct;100(10):1841-4. doi: 10.2105/AJPH.2010.193060. Epub 2010 Aug 19.
Developments regarding human papillomavirus (HPV) vaccines will transform HPV vaccination in the United States while simultaneously raising several new policy and ethical concerns. Policymakers, vaccine manufacturers, and the public health community must now respond to the presence of competing vaccines that are similar but distinct, particularly with respect to genital wart prevention and the benefits of vaccinating males. This work arises in the shadow of the contentious introduction of the HPV vaccine Gardasil (Merck & Co, Inc, Whitehouse Station, NJ) in 2006, particularly the opposition to efforts in many states to require the vaccine for school attendance. I review the current status of HPV vaccine policy in the United States and examine issues of public health ethics and policy central to ongoing and future HPV vaccination programs.
人乳头瘤病毒（HPV）疫苗的发展将改变美国的 HPV 疫苗接种，同时引发若干新的政策和伦理问题。政策制定者、疫苗制造商和公共卫生界现在必须应对具有相似但又不同的竞争疫苗的出现，特别是在预防生殖器疣和接种男性疫苗的益处方面。这项工作是在 2006 年有争议地引入 HPV 疫苗 Gardasil（默克公司，新泽西州怀特豪斯站）的背景下开展的，特别是在许多州反对为了上学而要求接种疫苗的努力。我回顾了美国 HPV 疫苗政策的现状，并研究了与正在进行和未来的 HPV 疫苗接种计划相关的公共卫生伦理和政策问题。
